CMX-2043 Treatment Limits Neural Injury Pathophysiology and Promotes Neurological and Cognitive Recovery in a Pediatric Porcine Traumatic Brain Injury Model
Traumatic brain injury (TBI) represents a major global health issue contributing to significant disability and mortality. The TBI-induced secondary injury cascade, characterized by neuroinflammation, neural cell death, and tissue damage, results in lifelong functional deficits. Alpha-<i>N</i>-[(R)-1, 2-dithiolane-3-pentanoyl]l-glutamyl-l-alanine (CMX-2043) is a novel alpha lipoic acid (ALA)-based therapeutic that has neuroprotective, anti-apoptotic, and anti-inflammatory properties that mitigate cellular, tissue, and functional deficits following TBI. In this study, we evaluated the therapeutic efficacy of CMX-2043 on neural injury severity and functional recovery in a clinically relevant porcine TBI model. CMX-2043 was administered 1-h post-TBI subcutaneously (SQ; <i>n</i> = 8) or intravenously (IV; <i>n</i> = 8) for a total of 5 days. Control piglets (placebo; <i>n</i> = 11) received saline subcutaneously. Magnetic resonance imaging (MRI), immunohistochemistry analysis, modified Rankin Scale (mRS) neurological evaluation, and social recognition testing (SRT) were evaluated up to 42 days post-TBI. MRI revealed that SQ and IV CMX-2043 administration reduced hemispheric swelling and atrophy, lesion volume, midline shift, and intracerebral hemorrhage and preserved diffusivity, cerebral blood flow, and white matter integrity. CMX-2043-mediated neuroprotection and regeneration were indicated by increased neural cell density, decreased neuroinflammation, and enhanced neurogenesis following SQ and IV administration. These cellular and tissue-level changes corresponded with reduced neurological deficits and rapid cognitive recovery as indicated by improved mRS and SRT results, respectively. Collectively, these results observed in a translational large animal porcine model suggest that CMX-2043 holds significant clinical value to potentially mitigate TBI pathophysiology and promote functional recovery.
Authors
- Erin E. Kaiser (ORCID: https://orcid.org/0000-0003-1521-950X)
- Sydney E. Sneed (ORCID: https://orcid.org/0000-0002-4839-9693)
- Kylee J. Duberstein
- Stephanie T. Dubrof
- Franklin D. West (ORCID: https://orcid.org/0000-0002-0504-7997)
- Deborah A. Barany (ORCID: https://orcid.org/0000-0002-1619-1513)
- Holly A. Kinder (ORCID: https://orcid.org/0000-0001-8310-7265)
- A. Baguisi
- Savannah R. Cheek (ORCID: https://orcid.org/0000-0002-4060-4154)
- Hea Jin Park (ORCID: https://orcid.org/0000-0002-1611-1077)
- John J. Stern
- Sarah L. Schantz
- Taylor H. LePage
- David A. DeWahl
Institutions
- University of Georgia (US)
- New England Disabled Sports (US)
Publication Details
- Journal
- Journal of Neurotrauma
- Published
- 2025-07-30
- DOI
- https://doi.org/10.1177/08977151251363584
- Primary Topic
- Traumatic Brain Injury Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00